PEPTIDE GUARDIANResearch literacy for peptides

Compounds / Mitochondrial and cellular

Glutathione

Also written as: Reduced glutathione, GSH, L-glutathione, gamma-L-glutamyl-L-cysteinylglycine, Tathion (a trade name listed by PubChem), Glutathione-SH

Known for
Best known for skin-lightening drips and pills, and talked about as a 'detox' and immune booster.
What studies show
In people, small short trials of pills and creams reported what reviewers described as modest skin lightening; the one placebo-controlled drip study in a 2025 review showed no clear benefit.

Glutathione is a small three-amino-acid molecule that every cell makes to protect itself from damage; human trials by mouth, by vein, by nose and by inhaler have produced mostly small, mixed or null results, and it is not an FDA-approved drug.

Where the evidence stands

  1. 1 of 4Animal and cell studies only
  2. 2 of 4Early human trials
  3. 3 of 4Late-stage human trials
  4. 4 of 4Approved medicine

The short version

  • Glutathione is a tripeptide (three amino acids: glutamate, cysteine and glycine) that cells make for themselves. It is not an FDA-approved drug in the United States.
  • Taken by mouth, it raised glutathione stores in one 6-month trial of 54 adults, but a 4-week trial of 40 adults found no change in glutathione or in markers of oxidative damage.
  • Given into a vein, by nose or by inhaler, it has not beaten placebo on the main outcome in the best-designed trials we found: Parkinson's disease (21 and 45 patients), cystic fibrosis (153 patients) and nerve damage from one chemotherapy combination (185 patients).
  • For skin lightening, small trials of glutathione by mouth or on the skin reported modest lightening; a 2025 systematic review called the intravenous form contraindicated because of lack of benefit and side effects.
  • The main caution: FDA has twice reported patients harmed by intravenous glutathione made from dietary-supplement-grade powder, with fever, chills, signs of shock and hospital stays, consistent with bacterial toxins (endotoxin).
  • In the United States glutathione is in FDA's Category 1 (under evaluation) for pharmacy compounding under both section 503A and section 503B. In 2022 FDA told its advisory committee it proposed not to allow it for 503A compounding; the committee voted 8 to 5, with 1 abstaining, to allow it. FDA has published no proposed or final rule.
  • Glutathione is not named on the 2026 or 2027 anti-doping Prohibited List, but the List separately prohibits intravenous infusions or injections above a set volume as a method, whatever they contain.

What it is

Glutathione is a very small peptide. It is made of three amino acids joined in a chain: glutamate, cysteine and glycine. Its full chemical name, gamma-L-glutamyl-L-cysteinylglycine, records an unusual detail: the glutamate is linked through a side part of the molecule (the 'gamma' position), not the usual backbone link. This is one reason ordinary digestive enzymes treat it differently from most peptides.

More on what it is and where it came from

Your body makes its own. A 2013 review describes glutathione as present in all mammalian tissues and as the most abundant thiol (sulfur-containing compound) in cells that is not part of a protein. The form usually sold is 'reduced' glutathione (GSH), the active form. When it does its protective job it is converted to an 'oxidised' form (GSSG), in which two glutathione molecules are joined, and cells then recycle it back.

It is sold as a dietary supplement by mouth, in skin creams, and as an injection or 'drip' in clinics and med spas, often for skin lightening. In the United States it is not an FDA-approved drug for any use. FDA has stated it has not approved any injectable product for skin lightening or whitening.

Glutathione is not a company invention; it is part of normal cell chemistry. It has been studied as a treatment for decades: the human trials on this page run from 1992 (a study of whether it is absorbed when swallowed) to 2025 (reviews of skin lightening). Trade names listed by PubChem, such as Tathion, show that it has been made as a medicine in some countries. The textbook history of its discovery (often credited to work in the late 1800s and 1920s) was not checked in a primary source for this page and is not given here.

How it is thought to work

Inside cells, glutathione acts as a protective buffer. A 2009 review describes three main jobs: it neutralises oxidants (reactive molecules that damage fats, proteins and DNA) by donating electrons to them; it attaches itself to toxic foreign chemicals so they can be removed (a process called conjugation); and it helps keep the cell's overall chemical balance (redox balance) stable. A 2013 review adds roles in immune function, cell growth and programmed cell death.

More on how it works

Cells build glutathione in two enzyme steps, in the cell's fluid (cytosol). The first enzyme, glutamate cysteine ligase, is the slow, controlling step, and the supply of cysteine is the main limit on how much is made. This is why some products try to supply cysteine (for example as N-acetylcysteine) rather than glutathione itself; those products are not covered on this page.

Whether glutathione taken from outside reaches cells intact is a central open question. In a 1992 study of 7 healthy volunteers, a single oral amount did not raise glutathione in blood over the following four and a half hours; the authors attributed this to breakdown by an enzyme (gamma-glutamyltransferase) in the gut and liver. A 2015 trial that lasted 6 months did find higher stores in blood and cheek cells, so the picture differs between single doses and long-term use. For skin, reviews describe a proposed mechanism of reducing the activity of tyrosinase (an enzyme that makes melanin pigment) and shifting pigment production toward a lighter type; this comes largely from laboratory work.

What is established in people

Glutathione taken by mouth raised body stores over 6 months in one trial of 54 adults, but a 4-week trial found no change, and an early study found that a single oral amount is broken down before it reaches the blood. The best-designed trials of glutathione by vein, nose spray or inhaler found no benefit over placebo on their main outcome in Parkinson's disease, cystic fibrosis and nerve damage from paclitaxel and carboplatin; one small 2002 trial with oxaliplatin chemotherapy was positive. Small, short trials of oral and topical glutathione reported modest skin lightening, while a 2025 systematic review called intravenous use for skin lightening contraindicated. No trial has established that glutathione injections or drips improve general health, energy, detoxification or ageing, and long-term safety by any route is unknown.

What the studies found

12 studies, human trials first. Each links to the paper or registry record.

  1. Human trial2017

    Phase IIb Study of Intranasal Glutathione in Parkinson's Disease

    All groups improved, including placebo.

    Full finding, who was studied, and limits

    Who: INTRANASAL (nose spray). 45 people with Parkinson's disease (Hoehn and Yahr stages 1 to 3); double-blind, placebo-controlled, two strengths versus placebo, 3 months plus a 1-month washout (Mischley et al.)

    All groups improved, including placebo. The higher-strength group improved from its own starting point on the total symptom score and the motor score, but neither glutathione group did better than placebo. The authors concluded the data 'do not suggest' intranasal glutathione is superior to placebo after three months. One participant in the higher-strength group developed cardiomyopathy (a disease of the heart muscle).

    Read with care: 45 people and 3 months. The large placebo response shows why uncontrolled reports of improvement in Parkinson's disease are unreliable.

    Journal of Parkinson's Disease · pubmed.ncbi.nlm.nih.gov

  2. Human trial2015

    Randomized controlled trial of oral glutathione supplementation on body stores of glutathione

    After 6 months, the higher-strength group had 30 to 35% more glutathione in red blood cells, plasma and lymphocytes (a type of white blood cell) and 260% more in cheek cells (p < 0.05).

    Full finding, who was studied, and limits

    Who: ORAL. 54 non-smoking adults; randomised, double-blind, placebo-controlled, two strengths versus placebo, 6 months plus a 1-month washout (Richie et al.)

    After 6 months, the higher-strength group had 30 to 35% more glutathione in red blood cells, plasma and lymphocytes (a type of white blood cell) and 260% more in cheek cells (p < 0.05). The lower-strength group had 17% and 29% increases in blood and red blood cells. A measure of immune cell activity (natural killer cell cytotoxicity) more than doubled in the higher-strength group at 3 months compared with placebo. Levels returned to baseline after the washout month.

    Read with care: Shows that stores rose, not that health improved; no clinical outcome was measured. Moderate size. Contrasts with the 4-week null trial above, possibly because of the longer duration. Adverse events were not reported in the abstract.

    European Journal of Nutrition · pubmed.ncbi.nlm.nih.gov

  3. Human trial2014

    North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study

    A null result.

    Full finding, who was studied, and limits

    Who: INTRAVENOUS. 185 people receiving paclitaxel and carboplatin chemotherapy (94 glutathione, 91 placebo); phase 3, randomised, double-blind, placebo-controlled, enrolled 2009 to 2011 (Leal et al.)

    A null result. Nerve damage (peripheral neuropathy) did not differ on a patient questionnaire (p = 0.21) or on clinician grading (p = 0.449). Time to moderate nerve damage favoured placebo (p = 0.039), and in patients on weekly paclitaxel an acute pain syndrome also favoured placebo (p = 0.002). No subgroup benefited. Time to cancer progression did not differ. The authors wrote that the results 'do not support the use of glutathione' for this purpose.

    Read with care: Applies to paclitaxel and carboplatin. Glutathione might behave differently with other chemotherapy drugs such as oxaliplatin or cisplatin (see the next items).

    Cancer · pubmed.ncbi.nlm.nih.gov

  4. Human trial2013

    Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial

    The main outcome was negative: lung function (FEV1, the amount of air blown out in one second) did not differ between groups (p = 0.180).

    Full finding, who was studied, and limits

    Who: INHALED. 153 people with cystic fibrosis aged 8 and over with moderately reduced lung function (73 glutathione, 80 placebo); randomised, double-blind, placebo-controlled, 6 months (Griese et al.)

    The main outcome was negative: lung function (FEV1, the amount of air blown out in one second) did not differ between groups (p = 0.180). An exploratory analysis found a gain of 2.2% of predicted lung function at 3 months that did not last. There were no fewer lung flare-ups (exacerbations) and no better quality of life. Glutathione levels in sputum rose, showing that the drug reached the lungs, but there was no sign of less oxidative stress or inflammation. Side effects were similar in both groups.

    Read with care: This is the largest trial we found of any glutathione route. Its negative main result is the most reliable finding on inhaled glutathione in cystic fibrosis.

    American Journal of Respiratory and Critical Care Medicine · pubmed.ncbi.nlm.nih.gov

  5. Human trial2012

    Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study

    The melanin index (an instrument reading of skin pigment) fell at all six measured sites with glutathione, but the fall was significantly greater than placebo at only two: the right side of the face (p = 0.021) and a sun-exposed forearm (p = 0.036).

    Full finding, who was studied, and limits

    Who: ORAL. 60 healthy medical students in Thailand; randomised, double-blind, placebo-controlled, 4 weeks; all 60 completed (Arjinpathana and Asawanonda)

    The melanin index (an instrument reading of skin pigment) fell at all six measured sites with glutathione, but the fall was significantly greater than placebo at only two: the right side of the face (p = 0.021) and a sun-exposed forearm (p = 0.036). Both glutathione and placebo were very well tolerated. The authors wrote that it 'results in a lightening of skin color in a small number of subjects' and that long-term safety has not been established.

    Read with care: Four weeks, 60 young healthy people, and significance at two of six sites. Instrument readings, not a visible change judged by patients or doctors.

    Journal of Dermatological Treatment · pubmed.ncbi.nlm.nih.gov

  6. Human trial2011

    Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers

    A null result.

    Full finding, who was studied, and limits

    Who: ORAL. 40 healthy adults enrolled, 39 completed; randomised, double-blind, placebo-controlled, 4 weeks (Allen and Bradley)

    A null result. There were no significant changes in markers of oxidative damage measured in urine (F2-isoprostanes, p = 0.38; 8-OHdG, a marker of DNA damage, p = 0.27). Measures of glutathione status in blood were also unchanged.

    Read with care: Short (4 weeks) and modest in size. Healthy volunteers, so there may have been little oxidative damage to reduce.

    Journal of Alternative and Complementary Medicine · pubmed.ncbi.nlm.nih.gov

  7. Human trial2009

    Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease

    Neither result was statistically significant.

    Full finding, who was studied, and limits

    Who: INTRAVENOUS. 21 people with Parkinson's disease (11 glutathione, 10 placebo); randomised, double-blind pilot, 4 weeks of treatment then 8 weeks of observation (Hauser et al.)

    Neither result was statistically significant. Over the 4 treatment weeks, a standard Parkinson's symptom score improved by 2.8 points more in the glutathione group than placebo (p = 0.32). Over the following 8 weeks it worsened by 3.5 points more in the glutathione group (p = 0.54). Glutathione was well tolerated and nobody withdrew because of side effects. The authors wrote that the data suggest 'the possibility of a mild symptomatic effect' that would need a larger study.

    Read with care: A pilot study with 21 patients, too small to detect a modest effect or to establish safety. The differences could be chance.

    Movement Disorders · pubmed.ncbi.nlm.nih.gov

  8. Human trial2002

    Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial

    After 8 cycles, 9 of 21 patients on glutathione had nerve damage compared with 15 of 19 on placebo.

    Full finding, who was studied, and limits

    Who: INTRAVENOUS. 52 people with advanced colorectal cancer receiving oxaliplatin chemotherapy, randomised to glutathione or salt-water placebo; 40 were assessable after the eighth cycle (Cascinu et al.)

    After 8 cycles, 9 of 21 patients on glutathione had nerve damage compared with 15 of 19 on placebo. Moderate to severe nerve damage was less common with glutathione (2 against 11 patients, p = 0.003). Tumour response rates were similar (26.9% against 23.1%), which the authors took to mean glutathione did not weaken the chemotherapy.

    Read with care: Small, single trial with many patients not assessable by the later cycles. Not confirmed by the larger 2014 trial with a different chemotherapy combination. The response-rate comparison was too small to rule out an effect on cancer treatment.

    Journal of Clinical Oncology · pubmed.ncbi.nlm.nih.gov

  9. Human trial1992

    The systemic availability of oral glutathione

    Glutathione in blood plasma did not rise significantly after swallowing it, and neither did its building blocks cysteine and glutamate.

    Full finding, who was studied, and limits

    Who: ORAL. 7 healthy volunteers, single oral amount, blood sampled for 270 minutes

    Glutathione in blood plasma did not rise significantly after swallowing it, and neither did its building blocks cysteine and glutamate. The authors concluded that 'the systemic availability of glutathione is negligible in man', and attributed this to breakdown in the gut and liver.

    Read with care: Seven people and a single dose, measured only in plasma. It does not rule out effects of long-term use, which a later 6-month trial suggested (see Richie et al. 2015).

    European Journal of Clinical Pharmacology · pubmed.ncbi.nlm.nih.gov

  10. Review2025

    Glutathione as a skin-lightening agent and in melasma: a systematic review

    Topical and oral glutathione were described as moderately effective for skin lightening, with effects that were not sustained after stopping.

    Full finding, who was studied, and limits

    Who: Systematic review of the past 10 years of studies of glutathione on the skin, by mouth and by vein, including five randomised trials and one open study of oral glutathione and one placebo-controlled study of intravenous glutathione

    Topical and oral glutathione were described as moderately effective for skin lightening, with effects that were not sustained after stopping. The single placebo-controlled intravenous study showed no clear benefit (the difference in responders was not statistically significant, p = 0.054), and intravenous glutathione was associated with side effects. The authors concluded that 'IV glutathione is contraindicated due to lack of efficacy and side effects'.

    Read with care: The underlying trials are small and short, and risk of bias was high in about half. The abstract does not give total participant numbers.

    International Journal of Dermatology · pubmed.ncbi.nlm.nih.gov

  11. Review2019

    Antioxidant supplementation for lung disease in cystic fibrosis

    Pooling the two inhaled-glutathione trials, lung function was 3.5% of predicted higher at 3 months, but the difference at 6 months (2.3%) was not statistically significant.

    Full finding, who was studied, and limits

    Who: 20 studies with 924 children and adults with cystic fibrosis; two inhaled-glutathione trials pooled (258 participants)

    Pooling the two inhaled-glutathione trials, lung function was 3.5% of predicted higher at 3 months, but the difference at 6 months (2.3%) was not statistically significant. Quality of life and time to first flare-up did not differ. Side effects showed little or no difference. Only one of the 20 studies was judged free of bias. The authors nonetheless wrote that inhaled and oral glutathione 'appear to improve lung function'.

    Read with care: Low-quality evidence. The positive wording of the conclusion rests on the 3-month result; the 6-month result, the larger trial's main outcome and the clinical outcomes were not significant.

    Cochrane Database of Systematic Reviews · pubmed.ncbi.nlm.nih.gov

  12. Review2014

    Interventions for preventing neuropathy caused by cisplatin and related compounds

    For glutathione, pooled clinician grading showed fewer cases of moderate or worse nerve damage (risk ratio 0.29, 95% confidence interval 0.10 to 0.85), described as borderline.

    Full finding, who was studied, and limits

    Who: 29 studies with 2,906 participants testing many protective agents; 7 glutathione trials with 387 participants

    For glutathione, pooled clinician grading showed fewer cases of moderate or worse nerve damage (risk ratio 0.29, 95% confidence interval 0.10 to 0.85), described as borderline. The review's main measure (objective sensory testing) could not be pooled for glutathione. Overall the authors concluded that 'the data are insufficient to conclude that any of the purported chemoprotective agents' prevent or limit this nerve damage.

    Read with care: Small trials with mostly subjective outcomes. Covers cisplatin and related platinum drugs only, and predates or does not include the 2014 paclitaxel/carboplatin trial's negative result.

    Cochrane Database of Systematic Reviews · pubmed.ncbi.nlm.nih.gov

Safety findings

  • FDA alert, 7 June 2019: seven outpatients who received an injection compounded with L-glutathione had nausea, vomiting, light-headedness, chills, body aches and sneezing within minutes of the infusion; one had low blood pressure and difficulty breathing and was taken to hospital. A second report described one more patient with chills, fever and shaking who was admitted for a possible bloodstream infection. FDA's laboratory found excessive bacterial endotoxin (fragments of bacteria that cause fever and shock-like reactions) in all samples tested, some up to five times the appropriate limit. The powder was labelled 'Caution: Dietary Supplement' and, FDA said, should not have been used to make sterile injectables. Source: fda.gov
  • FDA notice, 27 August 2026: FDA is aware of reports of at least 30 patients with adverse events after intravenous glutathione, alone or combined with other ingredients, made by several compounding pharmacies from one supplier's dietary-supplement-grade lot. Reported events included fever, chills, pain, dizziness, signs of shock and sepsis-like symptoms, and some patients were hospitalised. FDA said these were consistent with exposure to excessive endotoxin, and that two Texas pharmacies had recalled glutathione injectables for elevated endotoxin. FDA said it was investigating. Source: fda.gov
  • FDA consumer update on injectable skin-lightening products (content current 2 September 2015, updated 26 September 2017): FDA said it has not approved any injectable products for skin lightening, that such products are unapproved new drugs that may be unsafe or ineffective and may contain unknown ingredients or contaminants, and that improper injection practices can cause infection and serious injury. Products named in seizures included glutathione kits. Source: fda.gov
  • Systematic review, 2025: intravenous glutathione for skin lightening was associated with side effects and showed no clear benefit in the one placebo-controlled study; oral and topical forms had side effects ranging from minimal to substantial depending on the study. Source: pubmed.ncbi.nlm.nih.gov
3 more safety findings
  • In the 45-patient intranasal Parkinson's trial, one participant in the higher-strength group developed cardiomyopathy (heart muscle disease). The abstract does not say whether it was judged to be caused by glutathione. Source: pubmed.ncbi.nlm.nih.gov
  • In controlled trials, side effects were generally similar to placebo: intravenous glutathione in 21 Parkinson's patients (no withdrawals for side effects), inhaled glutathione in 153 people with cystic fibrosis, and intravenous glutathione in 185 chemotherapy patients (no apparent differences in toxicity). In the last trial, however, time to moderate nerve damage and an acute pain syndrome with weekly paclitaxel both favoured placebo. Source: pubmed.ncbi.nlm.nih.gov
  • Long-term safety is not established by any route. The authors of the 60-person oral skin trial wrote that long-term safety 'has not been established and warrants more extensive clinical trials'. Source: pubmed.ncbi.nlm.nih.gov

Rules and status

Not an FDA-approved drug for any use, and FDA has said it has not approved any injectable product for skin lightening. For compounding, glutathione is in FDA's Category 1 (under evaluation) under both section 503A (pharmacies) and section 503B (outsourcing facilities). Category 1 is not approval. In 2022 FDA proposed not to add it to the 503A list; no final decision has been published.

The full history, with dates

Approval: there is no FDA-approved glutathione drug. On FDA's 503B category list (updated 21 March 2025, the version on FDA's site in November 2026), substances that are components of FDA-approved drugs are marked with two asterisks; the 'Glutathione' entry has none. FDA's consumer update on injectable skin-lightening products (content current 2 September 2015, updated 26 September 2017) states that FDA has not approved any injectable products for skin lightening. Pharmacy compounding (section 503A): FDA's list of nominated bulk drug substances, updated 14 May 2026, places 'Glutathione' in Category 1, 'Bulk Drug Substances Under Evaluation'. Category 1 is not a finding that the substance is safe or effective. Glutathione does not appear on FDA's page of substances that may present significant safety risks (Category 2 and withdrawn nominations; content current 22 April 2026). What FDA and its advisers have said: at the Pharmacy Compounding Advisory Committee meeting of 8 June 2022, FDA reviewed glutathione for a long list of nominated uses, including skin lightening, cystic fibrosis, asthma, chronic obstructive pulmonary disease, reducing side effects of chemotherapy, heavy metal poisoning, autism spectrum disorder, Alzheimer's disease, Parkinson's disease and others. The committee was told that 'FDA is proposing that glutathione NOT be included on the 503A Bulks List' and voted 8 yes, 5 no, 1 abstain to include it. The approved minutes record that members voting yes cited patient access, stability data and no compelling evidence of safety concerns, while members voting no cited a lack of scientific evidence of effectiveness for the conditions evaluated. Announced versus in effect: an advisory committee vote is advice, not a decision. A Federal Register search on 18 November 2026 found no proposed or final rule on glutathione, so it remains in Category 1. Outsourcing facilities (section 503B): FDA's 503B category list (21 March 2025) also places 'Glutathione' in Category 1. Other 2026 developments: the HHS draft enforcement-discretion policy for certain peptides (Federal Register notice of 30 October 2026, 91 FR 68526) names six peptides in Appendix A, and glutathione is not one of them (Appendix read from an Internet Archive capture of 15 November 2026). FDA's 2026 notice on supplement-grade glutathione does not address its compounding category. Dietary supplements: FDA's 2019 and 2026 notices describe glutathione ingredients labelled and sold as dietary-supplement grade and say such ingredients are not appropriate for injectable drugs. We did not find an FDA document that rules on whether glutathione qualifies as a dietary ingredient, so its supplement status is not stated here. Outside the United States: the Philippine FDA has warned against injectable glutathione for skin lightening (Advisory No. 2019-182; we could not open the advisory itself).

Source: fda.gov (source dated 2026-05-14)

In sport: Not named on the Prohibited List. We searched the full text of the 2026 List (in force 1 January to 31 December 2026) and the 2027 List (published 21 September 2026, in force from 1 January 2027), including their indexes, and found no entry for glutathione. Two general rules are relevant. Section M2.2 of both Lists prohibits, at all times, 'Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.' This rule is about the method and applies whatever the fluid contains. Section S0 prohibits any pharmacological substance not addressed elsewhere on the List 'with no current approval by any governmental regulatory health authority for human therapeutic use'; the 2027 List adds peptides as a named example. Glutathione is not FDA-approved, but injectable glutathione is reported to be approved in some other countries (for example, the Philippines, as an add-on in cisplatin chemotherapy, according to an advisory we could not open). We did not verify any approval, so we cannot say how S0 applies. This is a description of the List, not advice; athletes should check with their anti-doping organisation. WADA

Claims and what the evidence supports

What people sayWhat the evidence supports
Glutathione drips or injections lighten or whiten skin.The only placebo-controlled intravenous study found in a 2025 systematic review showed no clear benefit, and the review's authors called intravenous glutathione contraindicated because of lack of efficacy and side effects. FDA has not approved any injectable product for skin lightening. Source: pubmed.ncbi.nlm.nih.gov
Glutathione pills are proven to lighten skin.Small, short trials reported modest changes in instrument readings of skin pigment. In a 4-week trial of 60 people, oral glutathione beat placebo at only two of six skin sites. A 2019 systematic review called the evidence still inconclusive, and a 2025 review said the effect was not sustained. Source: pubmed.ncbi.nlm.nih.gov
Swallowed glutathione is useless because it is all digested.Partly true for a single dose: in 7 volunteers, one oral amount did not raise blood glutathione. But a 6-month trial of 54 adults found higher glutathione stores in blood and cheek cells, so long-term use did change measured levels. Whether that improves health was not tested. Source: pubmed.ncbi.nlm.nih.gov
Glutathione treats Parkinson's disease.A 21-patient pilot of intravenous glutathione found no statistically significant difference from placebo, and a 45-patient trial of a glutathione nose spray found it no better than placebo after three months; everyone, including the placebo group, improved. Source: pubmed.ncbi.nlm.nih.gov
Glutathione 'detoxes' the body or boosts the immune system.Glutathione does help cells neutralise oxidants and remove some toxic chemicals; that is cell biology, not proof that extra glutathione helps healthy people. A 4-week trial in 40 healthy adults found no change in markers of oxidative damage. A 6-month trial reported higher natural killer cell activity at 3 months, a laboratory measure, not a clinical benefit. Source: pubmed.ncbi.nlm.nih.gov
Glutathione protects against chemotherapy nerve damage.Mixed. A 52-patient trial with oxaliplatin was positive, but a 185-patient phase 3 trial with paclitaxel and carboplatin found no benefit, with two outcomes favouring placebo. A Cochrane review found the evidence insufficient to recommend any protective agent. Source: pubmed.ncbi.nlm.nih.gov
Glutathione is natural, so an IV drip is harmless.FDA has reported patients harmed by intravenous glutathione made from dietary-supplement-grade powder: 8 patients in 2019 and at least 30 in 2026, with fever, chills, signs of shock and hospital stays, consistent with endotoxin contamination. Source: fda.gov

What a genuine lab report should show

  • Identity by mass spectrometry matching the expected molecular weight: PubChem lists reduced glutathione (C10H17N3O6S) at 307.33 g/mol.
  • Purity by HPLC with the chromatogram shown. For glutathione the report should also state how much oxidised glutathione (GSSG, two molecules joined together) is present, because the reduced form converts to the oxidised form on exposure to air; a report that does not distinguish the two forms is incomplete.
  • The grade of the starting material. Both FDA alerts on harmed patients traced to glutathione labelled as dietary-supplement grade being used to make injections. A genuine certificate should say whether the material is pharmaceutical grade and name the original manufacturer, not only a repackager; FDA asked suppliers and repackagers to identify the upstream manufacturer.
  • Bacterial endotoxin and sterility results for anything presented as injectable. FDA found endotoxin up to five times the appropriate limit in the 2019 case. FDA has also said that testing alone should not be relied on to ensure quality.
  • The CAS number 70-18-8, a batch or lot number, the test date and the name of the laboratory, so the report can be traced to the actual material.
  • A lab report describes one batch of a chemical. It is not evidence that the compound is safe or effective in people.

How to read a lab report

What is not known

  • Does long-term oral glutathione improve any health outcome? The 6-month trial showed higher stores, the 4-week trial showed nothing, and neither measured a clinical outcome.
  • Does intravenous glutathione help any condition? The trials we found (Parkinson's disease, chemotherapy nerve damage) were small or negative, except one 52-patient oxaliplatin trial that has not been confirmed.
  • The 2019 Cochrane review on cystic fibrosis concluded that inhaled glutathione 'appears' to improve lung function, while the largest trial's main outcome was negative and the 6-month pooled result was not significant. Sources disagree in emphasis.
  • FDA proposed in 2022 not to place glutathione on the 503A list, and its advisers voted 8 to 5 (1 abstaining) to include it. FDA has published no proposed or final rule since. This page needs re-checking if a rule appears.
  • The Philippine FDA advisory (No. 2019-182) could not be opened (403 Forbidden). Its contents, including that injectable glutathione is approved there only as an add-on in cisplatin chemotherapy, come from search summaries and press reports and are unverified.
  • Whether injectable glutathione is approved by any government health regulator (for example in the Philippines, Italy or Japan, where trade names such as Tathion exist) was not verified. This matters for how WADA's S0 rule would apply.
  • We found no FDA document ruling on whether glutathione qualifies as a dietary ingredient for supplements, so its US supplement status is not stated.
  • The English version of FDA's consumer update on injectable skin-lightening products returned 404 Not Found; we relied on FDA's own Tagalog version of the same update (same dates).
  • The cause of the cardiomyopathy case in the intranasal Parkinson's trial was not stated in the abstract.
  • The single placebo-controlled intravenous skin-lightening trial was described only through the 2025 systematic review; we did not identify or open the original paper.

Sources

All 34 sources
  1. PubChem: Glutathione, CID 124886 (formula, molecular weight, IUPAC name, synonyms including CAS 70-18-8). pubchem.ncbi.nlm.nih.gov
  2. Forman, Zhang and Rinna 2009, Glutathione: overview of its protective roles, measurement, and biosynthesis (Mol Aspects Med). pubmed.ncbi.nlm.nih.gov
  3. Lu 2013, Glutathione synthesis (Biochim Biophys Acta). pubmed.ncbi.nlm.nih.gov
  4. Witschi et al. 1992, The systemic availability of oral glutathione (Eur J Clin Pharmacol). pubmed.ncbi.nlm.nih.gov
  5. Allen and Bradley 2011, oral glutathione and oxidative stress biomarkers, 40 volunteers (J Altern Complement Med). pubmed.ncbi.nlm.nih.gov
  6. Richie et al. 2015, oral glutathione and body stores, 6-month trial in 54 adults (Eur J Nutr). pubmed.ncbi.nlm.nih.gov
  7. Hauser et al. 2009, intravenous glutathione in Parkinson's disease, pilot of 21 patients (Mov Disord). pubmed.ncbi.nlm.nih.gov
  8. Mischley et al. 2015, phase I/IIa intranasal glutathione in Parkinson's disease, 30 patients (Mov Disord). pubmed.ncbi.nlm.nih.gov
  9. Mischley et al. 2017, phase IIb intranasal glutathione in Parkinson's disease, 45 patients (J Parkinsons Dis). pubmed.ncbi.nlm.nih.gov
  10. Griese et al. 2013, inhaled glutathione in cystic fibrosis, 153 patients (Am J Respir Crit Care Med). pubmed.ncbi.nlm.nih.gov
  11. Cochrane 2019, antioxidant supplementation for lung disease in cystic fibrosis. pubmed.ncbi.nlm.nih.gov
  12. Leal et al. 2014, NCCTG/Alliance N08CA, glutathione and paclitaxel/carboplatin neuropathy, 185 patients (Cancer). pubmed.ncbi.nlm.nih.gov
  13. Cascinu et al. 2002, glutathione and oxaliplatin neuropathy, 52 patients (J Clin Oncol). pubmed.ncbi.nlm.nih.gov
  14. Cochrane 2014, interventions for preventing neuropathy caused by cisplatin and related compounds. pubmed.ncbi.nlm.nih.gov
  15. Arjinpathana and Asawanonda 2012, oral glutathione as a whitening agent, 60 participants (J Dermatolog Treat). pubmed.ncbi.nlm.nih.gov
  16. 2021 trial of combined topical and oral glutathione for skin whitening, 46 participants (Int J Dermatol). pubmed.ncbi.nlm.nih.gov
  17. 2019 systematic review, glutathione and skin colour (J Cosmet Dermatol). pubmed.ncbi.nlm.nih.gov
  18. 2025 systematic review, glutathione as a skin-lightening agent and in melasma (Int J Dermatol). pubmed.ncbi.nlm.nih.gov
  19. 2025 systematic review, topical glutathione in dermatology (J Clin Aesthet Dermatol). pubmed.ncbi.nlm.nih.gov
  20. Sonthalia et al. 2016, Glutathione as a skin whitening agent: facts, myths, evidence and controversies (Indian J Dermatol Venereol Leprol). pubmed.ncbi.nlm.nih.gov
  21. FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables (7 June 2019). fda.gov
  22. FDA reminds compounders not to use dietary supplement grade glutathione for injectables (27 August 2026). fda.gov
  23. FDA consumer update: injectable skin lightening products (Tagalog version opened; content current 2 September 2015, updated 26 September 2017). fda.gov
  24. FDA consumer update: Injectable Skin Lightening and Skin Bleaching Products May Be Unsafe (English version; returned 404 when checked). fda.gov
  25. FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list, updated 14 May 2026; glutathione in Category 1). fda.gov
  26. FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (category list, updated 21 March 2025; glutathione in Category 1, no double asterisk). fda.gov
  27. FDA Pharmacy Compounding Advisory Committee, summary minutes of 8 June 2022 meeting (glutathione vote 8 yes, 5 no, 1 abstain). fda.gov
  28. FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current 22 April 2026; glutathione not listed). fda.gov
  29. Federal Register, 30 October 2026: HHS draft enforcement-discretion policy for certain peptides (91 FR 68526). govinfo.gov
  30. HHS 503A peptide enforcement-discretion policy, Appendix B (Appendix A names six peptides, not glutathione; read from an Internet Archive capture). hhs.gov
  31. Philippine FDA Advisory No. 2019-182, Unsafe use of glutathione as skin lightening agent (could not be opened: 403). fda.gov.ph
  32. WADA 2026 Prohibited List (S0, M2.2, index). wada-ama.org
  33. WADA 2027 Prohibited List (published 21 September 2026). wada-ama.org
  34. WADA 2027 List summary of major modifications and explanatory notes. wada-ama.org

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sign up and it opens right away.